CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.

ABSTRACT:

Purpose

Glioblastoma (GBM) patients suffer from a dismal prognosis, with standard of care therapy inevitably leading to therapy-resistant recurrent tumors. The presence of cancer stem cells (CSCs) drives the extensive heterogeneity seen in GBM, prompting the need for novel therapies specifically targeting this subset of tumor-driving cells. Here, we identify CD70 as a potential therapeutic target for recurrent GBM CSCs.

Experimental design

In the current study, we identified the relevance and functional influence of CD70 on primary and recurrent GBM cells, and further define its function using established stem cell assays. We use CD70 knockdown studies, subsequent RNAseq pathway analysis, and in vivo xenotransplantation to validate CD70's role in GBM. Next, we develop

SUBMITTER: Seyfrid M 

PROVIDER: S-EPMC8753449 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature